Mohamad Anas Al Tahan

Dr. Mohamad Anas Al Tahan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2024 in Molecular Pharmaceutics
Verified
Journal Article
Open access
KMKyprianos Michaelides
Kyprianos Michaelides
MTMohamad Anas Al Tahan
Mohamad Anas Al Tahan
YZYundong Zhou
Yundong Zhou
GTGustavo F. Trindade
Gustavo F. Trindade
DCDavid J. H. Cant
David J. H. Cant
AAAli Al-khattawi
Ali Al-khattawi
Spray drying is one of the leading manufacturing methods for active pharmaceutical ingredients (APIs) owing to its rapid, single-step, and cost-effective nature. It also has the capacity to generate microspheres capable of controlled release of APIs including biomolecules and vaccines. However, one of the key challenges of spray-dried formulations especially with poly(lactic-co-glycolic acid) (PLGA)-based controlled-release injectables is burst release, where a significant fraction of the API is released prematurely within a short period of time following administration, leading to detrimental impact on the performance and quality of end products. This study uses a model API, bovine serum albumin (BSA) protein, to identify the sources of burst release that may affect the kinetics and performance of long-acting injectable microsphere formulations. Spray-dried microspheres with various formulations (i.e., variable BSA/PLGA ratios) were characterized in terms of their morphology, particle size, surface area, thermal properties, moisture content, as well as chemical compositions and their distributions to investigate the impact of spray drying on the burst release phenomenon. The results suggest that a relatively high initial release (85%) observed is mainly attributed to the protein distribution close to the particle surface. Morphology analysis provided evidence that the microspheres retained their spherical structure during the burst release phase. X-ray photoelectron spectroscopy, hard X-ray photoelectron spectroscopy, and argon cluster sputtering-assisted time-of-flight secondary ion mass spectrometry analysis suggest an enrichment of PLGA on particle surfaces with buried BSA protein. The statistically significant difference in particle size and surface area between three different formulations may be responsible for an initial variation in release but did not seem to alter the overall burst release profile. Considering the suggested source of burst release, the two-fluid spray-drying method, characterized by a single liquid feed delivering a preprepared emulsion, generated matrix-type microspheres with a surface layer of PLGA, as evidenced by surface analysis. The PLGA surface layer proved to be prone to degradation and pore formation, allowing for faster diffusion of BSA out of the microspheres, resulting in a burst release. Increasing the polymer concentration did not seem to halt this process.

2 May 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
MTMohamad Anas Al Tahan
Mohamad Anas Al Tahan
MMMandeep Marwah
Mandeep Marwah
HEHind El-Zein
Hind El-Zein
STSana Al Tahan
Sana Al Tahan
LSLissette Sanchez-Aranguren
Lissette Sanchez-Aranguren
Nanotechnology has revolutionised pharmaceutical sciences, with mesoporous silica nanoparticles (MSNs) extensively studied as drug carriers. However, their clinical translation is hindered by challenges such as toxicity, tumour accumulation, and uncontrolled endocytosis. Mesoporous silica microparticles (MSMs) have emerged as a safer alternative, offering enhanced drug loading, controlled release, and improved formulation properties. MSMs facilitate protein delivery, solubility enhancement, and bioavailability improvement through pore size modulation, amorphous drug loading, and surface functionalisation. Additionally, they aid in overcoming multi-drug resistance and enable organ-specific targeting using aptamers or magnetic nanoparticles. Beyond drug delivery, MSMs enhance pharmaceutical formulations, with commercial products such as SYLOID®, Aeroperl®, and Neusilin® improving tablet performance and drug stability. Their role in controlled release systems further underscores their pharmaceutical potential. As research advances, MSMs offer promising strategies for precision medicine and optimised drug delivery, reinforcing their potential for future clinical applications.

8 December 2024 in Journal of Drug Targeting
Verified
Journal Article
Open access
LSLissette Sanchez-Aranguren
Lissette Sanchez-Aranguren
MTMohamad Anas Al Tahan
Mohamad Anas Al Tahan
MUMuhammad Uppal
Muhammad Uppal
PJParag Juvale
Parag Juvale
MMMandeep Kaur Marwah
Mandeep Kaur Marwah
Liposomes, as nanocarriers for therapeutics, are a prominent focus in translational medicine. Given their biocompatibility, liposomes are suitable drug delivery systems rendering highly efficient therapeutic outcomes with minimal off-site toxicity. In different scenarios of human disease, it is essential not only to maintain therapeutic drug levels but also to target them to the appropriate intracellular compartment. Mitochondria regulate cellular signalling, calcium balance, and energy production, playing a crucial role in various human diseases. The notion of focusing on mitochondria for targeted drug delivery was proposed several decades ago, yet the practical application of this idea and its translation to clinical use is still in development. Mitochondrial-targeted liposomes offer an alternative to standard drug delivery systems, potentially reducing off-target interactions, side effects, and drug dosage or frequency. . To advance this field, it is imperative to integrate various disciplines such as efficient chemical design, pharmacology, pharmaceutics, and cell biology. This review summarises scientific advances in the design, development and characterisation of novel liposome-based drug delivery systems targeting the mitochondria while revisiting their translational potential.

18 November 2024 in British Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
MTMohamad Anas Al Tahan
Mohamad Anas Al Tahan
STSana Al Tahan
Sana Al Tahan
Mitochondria, known as the cell’s powerhouse, play a critical role in energy production, cellular maintenance, and stemness regulation in non-cancerous cells. Despite their importance, using drug delivery systems to target the mitochondria presents significant challenges due to several barriers, including cellular uptake limitations, enzymatic degradation, and the mitochondrial membranes themselves. Additionally, barriers in the organs to be targetted, along with extracellular barriers formed by physiological processes such as the reticuloendothelial system, contribute to the rapid elimination of nanoparticles designed for mitochondrial-based drug delivery. Overcoming these challenges has led to the development of various strategies, such as molecular targeting using cell-penetrating peptides, genomic editing, and nanoparticle-based systems, including porous carriers, liposomes, micelles, and Mito-Porters. Porous carriers stand out as particularly promising candidates as drug delivery systems for targeting the mitochondria due to their large pore size, surface area, and ease of functionalisation. Depending on the pore size, they can be classified as micro-, meso-, or macroporous and are either ordered or non-ordered based on both size and pore uniformity. Several methods are employed to target the mitochondria using porous carriers, such as surface modifications with polyethylene glycol (PEG), incorporation of targeting ligands like triphenylphosphonium, and capping the pores with gold nanoparticles or chitosan to enable controlled and triggered drug delivery. Photodynamic therapy is another approach, where drug-loaded porous carriers generate reactive oxygen species (ROS) to enhance mitochondrial targeting. Further advancements have been made in the form of functionalised porous silica and carbon nanoparticles, which have demonstrated potential for effective drug delivery to mitochondria. This review highlights the various approaches that utilise porous carriers, specifically focusing on silica-based systems, as efficient vehicles for targeting mitochondria, paving the way for improved drug delivery strategies in mitochondrial therapies.

26 June 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
MTMohamad Anas Al Tahan
Mohamad Anas Al Tahan
AAAli Al-Khattawi
Ali Al-Khattawi
CRCraig Russell
Craig Russell

4 September 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
MMMandeep Marwah
Mandeep Marwah
BMBahareh Manhoosh
Bahareh Manhoosh
HSHala Shokr
Hala Shokr
MTMohamad Anas Al Tahan
Mohamad Anas Al Tahan
RSRoderick Stewart
Roderick Stewart
LSLissette Sanchez-Aranguren
Lissette Sanchez-Aranguren